Literature DB >> 11996323

Absorption, distribution and excretion of 3H-labeled cephaeline- and emetine-spiked ipecac syrup in rats.

Takayuki Asano1, Kazuhisa Ishihara, Yoko Wakui, Toshihiko Yanagisawa, Masayuki Kimura, Hideo Kamei, Takemi Yoshida, Yukio Kuroiwa, Yuichi Fujii, Mamoru Yamashita, Takanori Kuramochi, Hiroki Tomisawa, Mitsuru Tateishi.   

Abstract

The maximum plasma radioactivity levels of tritium (3H)-labeled cephaeline, (24.3, 28.7 and 40.6 ng eq./mL) were reached at 2.00-3.33 hours following oral dosing of ipecac syrup. The maximum plasma radioactivity levels of 3H-emetine (2.71, 6.47 and 9.62 ng eq./mL) were reached at 1.08-2.33 hours following ipecac syrup administration. The Cmax values of 3H-cephaeline were followed by a biexponential decrease with half-lives t 1/2(lambda z) of 3.45-9.40 hours. On the other hand, the t 1/2 (lambda z)of 3H-emetine were 65.4-163 hours, which revealed a biexponential decrease. The radioactivity of both tritium-labeled compounds was distrbuted maximally in most tissues at 24 hours. For 3H-cephaeline, the maximum radioactivity levels in tissues were approximately 100-150 times greater than in plasma. For 3H-emetine, the radioactivity levels in tissues were approximately 1000-3000 times greater than in plasma. Tissue radioactivity levels decreased at a substantially slower rate than that observed in plasma. Tissue radioactivity of 3H-emetine decreased more slowly than that of 3H-cephaeline. For 3H-cephaeline, the cumulative biliary excretion of radioactivity was 57.5% at 48 hours. The cumulative urinary and fecal excretion of radioactivity in these rats was 16.5% and 29.1%, respectively, of the dose at 48 hours following dosing. For 3H-emetine, the cumulative biliary excretion of radioactivity was 12.5% at 48 hours. The cumulative urinary and fecal excretion of radioactivity was 9.4% and 34.1%, respectively, of the administered dose at 48 hours. The radioactivity level of 3H-emetine remaining in the carcasses at 48 hours was equivalent to approximately 50% of the dose. A portion of each tritium-labeled compound was subjected to entero-hepatic circulation. Thus, the absorption rate of 3H-cephaeline and 3H-emetine was estimated to be approximately 70% on the basis of the data obtained from excretion studies. There was no difference in the absorption process between these two compounds. However, the difference was admitted in the biliary clearance, which is the main excretion route of both compounds. Delayed excretion of 3H-emetine may be primarily due to its resorption as related to entero-hepatic circulation and tissue retention. This study has determined the absorption, distribution and excretion of 3H-cephaeline and 3H-emetine in rats.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996323     DOI: 10.1007/BF03190401

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  Residual gastric content after gastric lavage and ipecacuanha-induced emesis in self-poisoned patients: an endoscopic study.

Authors:  J P Saetta; D N Quinton
Journal:  J R Soc Med       Date:  1991-01       Impact factor: 5.344

Review 2.  Position statement: ipecac syrup. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.

Authors:  E P Krenzelok; M McGuigan; P Lheur
Journal:  J Toxicol Clin Toxicol       Date:  1997

3.  Ipecac as a cause of the Mallory-Weiss syndrome.

Authors:  G A Timberlake
Journal:  South Med J       Date:  1984-06       Impact factor: 0.954

4.  Death resulting from ipecac syrup poisoning.

Authors:  A G Adler; P Walinsky; R A Krall; S Y Cho
Journal:  JAMA       Date:  1980-05-16       Impact factor: 56.272

5.  Nonemetic effects of ipecac syrup.

Authors:  P A Czajka; S L Russell
Journal:  Pediatrics       Date:  1985-06       Impact factor: 7.124

Review 6.  Special considerations in gastrointestinal decontamination.

Authors:  J Perrone; R S Hoffman; L R Goldfrank
Journal:  Emerg Med Clin North Am       Date:  1994-05       Impact factor: 2.264

7.  Toxicology of ipecac: a review.

Authors:  B R Manno; J E Manno
Journal:  Clin Toxicol       Date:  1977       Impact factor: 4.467

8.  Emetine myopathy: two case reports with pathobiochemical analysis.

Authors:  H Sugie; R Russin; M A Verity
Journal:  Muscle Nerve       Date:  1984-01       Impact factor: 3.217

9.  A model system for measuring comparative toxicities of cardiotoxic drugs with cultured rat heart myocytes, endothelial cells and fibroblasts. I. Emetine, chloroquine and metronidazole.

Authors:  D G Wenzel; G N Cosma
Journal:  Toxicology       Date:  1984-11       Impact factor: 4.221

10.  Absorption of ipecac alkaloids in emergency patients.

Authors:  D M Moran; D J Crouch; B S Finkle
Journal:  Ann Emerg Med       Date:  1984-12       Impact factor: 5.721

View more
  3 in total

1.  Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences.

Authors:  Aoli Wang; Yong Sun; Qingwang Liu; Hong Wu; Juan Liu; Jun He; Junling Yu; Qing Qing Chen; Yinglu Ge; Zhuhui Zhang; Chen Hu; Cheng Chen; Ziping Qi; Fengming Zou; Feiyang Liu; Jie Hu; Ming Zhao; Tao Huang; Beilei Wang; Li Wang; Wei Wang; Wenchao Wang; Tao Ren; Jing Liu; Yehuan Sun; Song Fan; Qibing Wu; Chaozhao Liang; Liangdan Sun; Bin Su; Wei Wei; Qingsong Liu
Journal:  Mol Biomed       Date:  2020-11-30

Review 2.  Different Aspects of Emetine's Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19.

Authors:  Mehdi Valipour
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-23

3.  Biotransformation of the ipecac alkaloids cephaeline and emetine from ipecac syrup in rats.

Authors:  Takayuki Asano; Junko Watanabe; Chiharu Sadakane; Kazuhisa Ishihara; Kazuhiro Hirakura; Yoko Wakui; Toshihiko Yanagisawa; Masayuki Kimura; Hideo Kamei; Takemi Yoshida; Yuichi Fujii; Mamoru Yamashita
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.